Randomized comparison of 5-FU alone or combined with mitomycin and cytarabine (MFC) in the treatment of advanced gastric cancer.
In a prospective randomized study, 53 patients with advanced gastric cancer previously untreated by chemotherapy were randomly assigned to treatment with 5-FU alone or combined with mitomycin and cytarabine (MFC). The response rate with MFC was higher (28%) than with 5-FU alone (21%). The difference, however, was not statistically significant. Median response duration was practically identical with 5-FU (16 weeks) and MFC (17 weeks). There was no difference in median survival between the two groups (39 and 43 weeks, respectively).
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D003561:Cytarabine / Q000008:administration & dosage* / Q000009:adverse effects; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage* / Q000009:adverse effects; D011379:Prognosis; D011446:Prospective Studies; D011897:Random Allocation; D013274:Stomach Neoplasms / Q000188:drug therapy*
D008937:Mitomycins; D003561:Cytarabine; D016685:Mitomycin; D005472:Fluorouracil